Kisqali, Femara Combo Shows Promise in HR+/HER2- Advanced Breast Cancer Patients
News
The latest results from the Phase 3 MONALEESA-2 study showed that adding Novartis’ Kisqali (ribociclib) to Femara (letrozole) for the treatment of breast cancer in certain postmenopausal women improves the time ... Read more